DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
Chimerix Presents Preliminary Data on Brincidofovir in Liver Transplant Recipients With Adenovirus Infections at IDWeek in San Diego
News | 10. 09. 2015
Chimerix
DURHAM, N.C., Oct. 7, 2015 – Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today preliminary data from liver transplant patients who received brincidofovir for adenovirus infection through the ongoing AdVise trial and the brincidofovir expanded access program. These data will be presented at IDWeek in San Diego.
